HRTX — Heron Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $251.21m
- $385.78m
- $144.29m
- 42
- 70
- 11
- 36
Annual income statement for Heron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 88.6 | 86.3 | 108 | 127 | 144 |
| Cost of Revenue | |||||
| Gross Profit | 52.4 | 40.3 | 52.8 | 61.9 | 106 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 317 | 304 | 282 | 238 | 156 |
| Operating Profit | -228 | -218 | -175 | -111 | -11.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -227 | -221 | -182 | -111 | -13.6 |
| Net Income After Taxes | -227 | -221 | -182 | -111 | -13.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -227 | -221 | -182 | -111 | -13.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -227 | -221 | -182 | -111 | -13.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.5 | -2.24 | -1.67 | -0.8 | -0.089 |